Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer

BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulves...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Leary, Ben, Cutts, Rosalind J, Huang, Xin, Hrebien, Sarah, Liu, Yuan, André, Fabrice, Loibl, Sibylle, Loi, Sherene, Garcia-Murillas, Isaac, Cristofanilli, Massimo, Bartlett, Cynthia Huang, Turner, Nicholas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936069/
https://www.ncbi.nlm.nih.gov/pubmed/32940689
http://dx.doi.org/10.1093/jnci/djaa087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936069/
https://www.ncbi.nlm.nih.gov/pubmed/32940689
http://dx.doi.org/10.1093/jnci/djaa087

Ejemplares similares